CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Investors optimistic about continued biotech and medtech IPO resurgence in 2025 [Yahoo! Finance]
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares